Skip to main content
SpringerLink
Log in

Chemotherapy in the Management of Retinoblastoma

  • Chapter
  • First Online:
Retinoblastoma

Part of the book series: Pediatric Oncology ((PEDIATRICO))

Abstract

Treatment of retinoblastoma aims to save life and preserve useful vision, and thus needs to be individualized. Factors that need to be considered include unilaterality or bilaterality of the disease, potential for vision, and intraocular and extraocular staging. A multidisciplinary approach is pivotal, and it is in this context that the role of chemotherapy must be discussed.

The first clinical experience with chemotherapy in the treatment of retinoblastoma using nitrogen mustard was reported in 1953 (Kupfer 1953). Institutional experiences in the management of extraocular retinoblastoma were reported subsequently, usually applying regimens modeled after the treatment regimens for metastatic neuroblastoma (Lonsdale et al. 1968; Pratt et al. 1985). Since then, the role of chemotherapy has been expanding, and now it is a main component in the management of intraocular disease.

Retinoblastoma is a very chemosensitive disease; in general, chemotherapy is indicated in patients with extraocular disease, in the subgroup of patients with intraocular disease with high-risk histologic features, and in patients with bilateral disease in conjunction with aggressive focal therapies. Agents with documented efficacy include microtubule inhibitors (vincristine and paclitaxel), platinum compounds (cisplatin and carboplatin), topoisomerase II inhibitors (teniposide and etoposide), alkylating agents (cyclophosphamide and ifosfamide), anthracyclines (doxorubicin and idarubicin), and topoisomerase I inhibitors (topotecan) (Schouten-van Meeteren et al. 2002; Rodriguez-Galindo et al. 2007).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abramson DH, Greenfield DS, Ellsworth RM (1992) Bilateral retinoblastoma: correlations between age at diagnosis and time course for new intraocular tumors. Ophthalmic Paediatr Genet 13:1-7

    Article  CAS  PubMed  Google Scholar 

  • Abramson DH, Gamell LS, Ellsworth RM et al (1994) Unilateral retinoblastoma: new intraocular tumours after treatment. Br J Ophthalmol 78:698-701

    Article  CAS  PubMed  Google Scholar 

  • Abramson DH, Frank C, Chantada G et al (1999a) Intraocular carboplatin concentrations following intravenous administration for human intraocular retinoblastoma. Ophthalmic Genet 20:31-36

    Article  CAS  PubMed  Google Scholar 

  • Abramson D, Frank C, Dunkel I (1999b) A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 106:1947-1950

    Article  CAS  PubMed  Google Scholar 

  • Abramson DH, Lawrence SD, Beaverson KL, Lee TC, Rollins IS, Dunkel IJ (2005) Systemic carboplatin for retinoblastoma: change in tumour size over time. Br J Ophthalmol 89:1616-1619

    Article  CAS  PubMed  Google Scholar 

  • Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP (2008) A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma: initial results. Ophthalmology 115:1398-1404

    Article  PubMed  Google Scholar 

  • Antonelli CBG, Steinhorst F, Ribeiro KCB et al (2003) Extraocular retinoblastoma: a 13-year experience. Cancer 98:1292-1298

    Article  Google Scholar 

  • Antonelli CBG, Ribeiro KCB, Steinhorts F, Novaes PERS, Chojniak MM, Malogolowkin M (2006) Treatment of retinoblastoma patients with chemoreduction plus local therapy: experience of the AC Camargo Hospital, Brazil. J Pediatr Hematol Oncol 28:342-345

    Article  Google Scholar 

  • Athale UH, Stewart C, Kuttesch JF et al (2001) Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol 20:88-95

    Article  Google Scholar 

  • Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF (1996) Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 37:195-202

    Article  CAS  PubMed  Google Scholar 

  • Blanco J, Dervieux T, Edick M et al (2001) Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci USA 98:10338-10343

    Article  CAS  PubMed  Google Scholar 

  • Blaney SM, Heideman R, Berg S et al (2003) Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 21:143-147

    Article  CAS  PubMed  Google Scholar 

  • Bu H-Z, Gukasyan HJ, Goulet L, Lou X-J, Xiang C, Koudriakova T (2007) Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab 8:91-107

    Article  CAS  PubMed  Google Scholar 

  • Carcaboso AM, Bramuglia GF, Chantada GL et al (2007) Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy. Invest Ophthalmol Vis Sci 48:3761-3767

    Article  PubMed  Google Scholar 

  • Chan HS, Canton MD, Gallie BL (1989) Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines. Anticancer Res 9:469-474

    CAS  PubMed  Google Scholar 

  • Chan H, DeBoer G, Thiessen J et al (1996) Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res 2:1499-1508

    CAS  PubMed  Google Scholar 

  • Chan H, Lu Y, Grogan T et al (1997) multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res 57:2325-2330

    CAS  PubMed  Google Scholar 

  • Chantada G, Davila MTG, Fandiño A et al (1999a) Retinoblastoma with low risk for extraocular relapse. Ophthalmic Genet 20:133-140

    Article  CAS  PubMed  Google Scholar 

  • Chantada G, Fandiño A, Mato G, Casak S (1999b) Phase II window of idarubicin in children with extraocular retinoblastoma. J Clin Oncol 17:1847-1850

    CAS  PubMed  Google Scholar 

  • Chantada G, Fandiño A, Casak S, Manzitti J, Raslawski E, Schvartzman E (2003) Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol 40:158-161

    Article  PubMed  Google Scholar 

  • Chantada G, Fandiño A, Dávila MTG et al (2004a) Results of a prospective study for the treatment of retinoblastoma. Cancer 100:834-842

    Article  CAS  PubMed  Google Scholar 

  • Chantada G, Fandino A, Casak S et al (2004b) Activity of topotecan in retinoblastoma. Ophthalmic Genet 25:37-43

    Article  CAS  PubMed  Google Scholar 

  • Chantada GL, Fandiño A, Raslawski EC et al (2005) Experience with chemoreduction and focal therapy for intraocular retinoblastoma in a developing country. Pediatr Blood Cancer 44:455-460

    Article  PubMed  Google Scholar 

  • Chantada GL, Casco F, Fandiño AC et al (2007) Outcome of patients with retinoblastoma and postlaminar optic nerve invasion. Ophthalmology 114:2083-2089

    Article  PubMed  Google Scholar 

  • Chantada GL, Fandino AC, Carcaboso AM et al (2009) A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci 50:1492-1496

    Article  PubMed  Google Scholar 

  • Chevez-Barrios P, Chintagumpala M, Mieler W et al (2005) Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by gancyclovir. J Clin Oncol 23:7927-7935

    Article  CAS  PubMed  Google Scholar 

  • Donovan SL, Schweers B, Martins R, Johnson D, Dyer MA (2006) Compensation by tumor suppressor genes during retinal development in mice and humans. BMC Biol 4:14

    Article  PubMed  CAS  Google Scholar 

  • Doz F, Khelfaoui F, Mosseri V et al (1994) The role of chemotherapy in orbital involvement of retinoblastoma. Cancer 74:722-732

    Article  CAS  PubMed  Google Scholar 

  • Doz F, Neuenschwander S, Plantaz D et al (1995) Etoposide and carboplatin in extraocular retinoblastoma: a study by the Société Française d’Oncologie Pédiatrique. J Clin Oncol 13:902-909

    CAS  PubMed  Google Scholar 

  • Dunkel I, Aledo A, Kernan N et al (2000) Successful treatment of metastatic retinoblastoma. Cancer 89:2117-2121

    Article  CAS  PubMed  Google Scholar 

  • Dunkel IJ, Lee TC, Shi W et al (2007) A phase II trial of carboplatin for intraocular retinoblastoma. Pediatr Blood Cancer 49:643-648

    Article  PubMed  Google Scholar 

  • Dyer MA, Rodriguez-Galindo C, Wilson MW (2005) Use of preclinical models to improve treatment of retinoblastoma. PLoS Med 2:e332

    Article  PubMed  CAS  Google Scholar 

  • Elison JR, Cobrinik D, Claros N, Abramson DH, Lee TC (2006) Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch Ophthalmol 124:1269-1275

    Article  CAS  PubMed  Google Scholar 

  • Eng G, Li FP, Abramson DH et al (1993) Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85:1121-1128

    Article  CAS  PubMed  Google Scholar 

  • Ericson LA, Rosengren BH (1961) Present therapeutic resources in retinoblastoma. Acta Ophthalmol 39:569-576

    CAS  Google Scholar 

  • Ericson LA, Kalberg B, Rosengren BH (1964) Trials of intravitreal injections of chemotherapeutic agents in rabbits. Acta Ophthalmol 42:721-726

    CAS  Google Scholar 

  • Fisher PG, Kadan-Lottick NS, Koroner DN (2002) Intrathecal thiotepa: reappraisal of an established therapy. J Pediatr Hematol Oncol 24:274-278

    Article  PubMed  Google Scholar 

  • Frangoul H, Ames MM, Mosher RB et al (1999) Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors: a report from the Children’s Cancer Group. Clin Cancer Res 5:3956-3962

    CAS  PubMed  Google Scholar 

  • Gallie B, Budning A, DeBoer G et al (1996) Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 114:1321-1328

    Article  CAS  PubMed  Google Scholar 

  • Ghate D, Edelhauser HF (2006) Ocular drug delivery. Expert Opin Drug Deliv 3:275-287

    Article  CAS  PubMed  Google Scholar 

  • Ghate D, Brook W, McCarey BE, Edelhauser HF (2007) Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci 48:2230-2237

    Article  PubMed  Google Scholar 

  • Gilbert JA, Simpson AE, Rudnick DE, Geroski DH, Aaberg TM, Edelhauser HF (2003) Transscleral permeability and intraocular concentrations of cisplatin from a collagen matrix. J Control Rel 20:409-417

    Article  CAS  Google Scholar 

  • Gombos D, Kelly A, Coen P, Kingston J, Hungerford J (2002) Retinoblastoma treated with primary chemotherapy alone: the significance of tumor size, location, and age. Br J Ophthalmol 86:80-83

    Article  PubMed  Google Scholar 

  • Gombos DS, Hungerford J, Abramson DH et al (2007) Secondary acute myelogenous leukemia in patients with retinoblastoma. Ophthalmology 114:1378-1383

    Article  PubMed  Google Scholar 

  • Gorodetsky R, Peylan-Ramu N, Reshef A, Gaberman E, Levdansky L, Marx G (2005) Interactions of carboplatin with fibrin(ogen), implications for local slow release chemotherapy. J Control Release 102:235-245

    Article  CAS  PubMed  Google Scholar 

  • Gündüz K, Shields CL, Shields JA et al (1998) The outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma. Arch Ophthalmol 116:1613-1617

    PubMed  Google Scholar 

  • Gündüz K, Muftuoglu O, Gunalp I, Unal E, Tacyildiz N (2006) Metastatic retinoblastoma: clinical features, treatment, and prognosis. Ophthalmology 113:1558-1566

    Article  PubMed  Google Scholar 

  • Harbour JW, Murray TG, Hamasaki D et al (1996) Local carboplatin therapy in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 37:1892-1898

    CAS  PubMed  Google Scholar 

  • Hayden B, Murray T, Scott I et al (2000) Subconjunctival carboplatin in retinoblastoma. Impact of tumor burden and dose schedule. Arch Ophthalmol 118:1549-1554

    Article  CAS  PubMed  Google Scholar 

  • Hayden BC, Jockovich M-E, Murray TG et al (2004) Pharmacokinetics of systemic versus focal carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci 45:3644-3649

    Article  PubMed  Google Scholar 

  • Heideman RL, Cole DE, Balis F et al (1989) Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49:736-741

    CAS  PubMed  Google Scholar 

  • Honavar SG, Singh A, Shields CL et al (2002) Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 120:923-931

    PubMed  Google Scholar 

  • Hungerford J, Toma N, Plowman P, Kingston J (1995) External beam radiotherapy for retinoblastoma: I Whole eye technique. Br J Ophthalmol 79:109-111

    Article  CAS  PubMed  Google Scholar 

  • Inomata M, Kaneko A (1987) Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res 78:858-868

    CAS  PubMed  Google Scholar 

  • Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA (1992) Effects of a Rb mutation in the mouse. Nature 359:295-300

    Article  CAS  PubMed  Google Scholar 

  • Jubran RF, Erdreich-Epstein A, Butturini A, Murphree AL, Villablanca JG (2004) Approaches to treatment for extraocular retinoblastoma. Children’s Hospital Los Angeles experience. J Pediatr Hematol Oncol 26:31-34

    Article  PubMed  Google Scholar 

  • Kaneko A, Suzuki S (2003) Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol 33:601-607

    Article  PubMed  Google Scholar 

  • Khelfaoui F, Validire P, Auperin A et al (1996) Histopathologic risk factors in retinoblastoma. A retrospective study of 172 patients treated in a single institution. Cancer 77:1206-1213

    Article  CAS  PubMed  Google Scholar 

  • Kingston J, Hungerford J, Madreperla S, Plowman P (1996) Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 114:1339-1343

    Article  CAS  PubMed  Google Scholar 

  • Kiratli H, Bilgiç S, Özerdem U (1998) Management of massive orbital involvement of intraocular retinoblastoma. Ophthalmology 105:322-326

    Article  CAS  PubMed  Google Scholar 

  • Kremens B, Wieland R, Reinhard H et al (2003) High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant 31:281-284

    Article  CAS  PubMed  Google Scholar 

  • Krishnakumar S, Mallikarjuna K, Desai N et al (2004) Multidrug resistance proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol 88:1521-1526

    Article  CAS  PubMed  Google Scholar 

  • Kupfer C (1953) Retinoblastoma treated with intravenous nitrogen mustard. Am J Ophthalmol 36:1721-1723

    CAS  PubMed  Google Scholar 

  • Laurie NA, Gray JK, Zhang J et al (2005) Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res 11:7569-7578

    Article  CAS  PubMed  Google Scholar 

  • Laurie NA, Donovan SL, Shih C-S et al (2006) Inactivation of the p53 pathway in retinoblastoma. Nature 444:61-66

    Article  CAS  PubMed  Google Scholar 

  • Lee EY, Chang CY, Hu N et al (1992) Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288-294

    Article  CAS  PubMed  Google Scholar 

  • Lee TC, Hayashi NI, Dunkel IJ, Beaverson K, Novetsky D, Abramson DH (2003) New retinoblastoma tumor formation in children initially treated with systemic carboplatin. Ophthalmology 110:1989-1995

    Article  PubMed  Google Scholar 

  • Li SL, Molokhia SA, Jeon EK (2004) Asessment of subconjunctival delivery with model ionic permeants and magnetic resonance imaging. Pharm Res 21:2175-2184

    Article  CAS  PubMed  Google Scholar 

  • Lonsdale D, Berry DH, Holcomb TM et al (1968) Chemotherapeutic trials in patients with metastatic retinoblastoma. Cancer Chemother Rep 52:631-634

    CAS  PubMed  Google Scholar 

  • Majumdar S, Mitra AK (2006) Chemical modification and formulation approaches to elevated drug transport accross cell membranes. Expert Opin Drug Deliv 3:511-527

    Article  CAS  PubMed  Google Scholar 

  • Mannermaa E, Vellonen K-S, Urtti A (2006) Drug transport in corneal epithelium and blood-retina barrier: Emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 58:1136-1163

    Article  CAS  PubMed  Google Scholar 

  • Marsubara H, Makimoto A, Higa T et al (2005) A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant 35:763-766

    Article  CAS  Google Scholar 

  • Mendelsohn M, Abramson DH, Madden T, Tong W, Tran H, Dunkel I (1998) Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol 116:1209-1212

    CAS  PubMed  Google Scholar 

  • Menon BS, Juraida E, Alagaratnam J et al (2007) Chemoreduction for intraocular retinoblastolma in Malaysia. J Pediatr Hematol Oncol 29:2-4

    Article  PubMed  Google Scholar 

  • Mohney B, Robertson D, Schomberg P, Hodge D (1998) Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy. Am J Ophthalmol 126:269-277

    Article  CAS  PubMed  Google Scholar 

  • Mohri M (1993) The technique of selective ophthalmic arterial infusion for conservative treatment of recurrent intraocular retinoblastoma. Keio Igaku 70:679-687

    Google Scholar 

  • Mulvihill A, Budning A, Jay V et al (2003) Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol 121:1120-1124

    Article  CAS  PubMed  Google Scholar 

  • Murphree A, Villablanca J, Deegan W et al (1996) Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 114:1348-1356

    Article  CAS  PubMed  Google Scholar 

  • Mustafa M, Jamshed A, Khafaga Y et al (1999) Adjuvant chemotherapy with vincristine, doxorubicin, and cyclophosphamide in the treatment of postenucleation high risk retinoblastoma. J Pediatr Hematol Oncol 21:364-369

    Article  CAS  PubMed  Google Scholar 

  • Namouni F, Doz F, Tanguy M et al (1997) High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer 33:2368-2375

    Article  CAS  PubMed  Google Scholar 

  • Nenadov Beck M, Balmer A, Dessing C, Pica A, Munier F (2000) First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 18:2881-2887

    Google Scholar 

  • Nishimura S, Sato T, Ueda H, Ueda K (2001) Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol 19:4182-4183

    CAS  PubMed  Google Scholar 

  • Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C (1998) Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 20:315-318

    Article  CAS  PubMed  Google Scholar 

  • Pardue MT, Hejny C, Gilbert JA, Phillips MJ, Geroski DH, Edelhauser HF (2004) Retinal function after subconjunctival injection of carboplatin in fibrin sealant. Retina 24:776-782

    Article  PubMed  Google Scholar 

  • Pratt CB, Crom DB, Howarth C (1985) The use of chemotherapy for extraocular retinoblastoma. Med Pediatr Oncol 13:330-333

    Article  CAS  PubMed  Google Scholar 

  • Pratt CB, Fontanesi J, Chenaille P et al (1994) Chemotherapy for extraocular retinoblastoma. Pediatr Hematol Oncol 11:301-309

    Article  CAS  PubMed  Google Scholar 

  • Pui C-H, Ribeiro RC, Hanckok M (1991) Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682-1687

    Article  CAS  PubMed  Google Scholar 

  • Ranta V-P, Urtti A (2006) Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev 58:1164-1181

    Article  CAS  PubMed  Google Scholar 

  • Robinson MR, Lee SS, Kim H et al (2006) A rabbit model for assessing the ocular barriers to the trasscleral delivery of triamcinolone acetonide. Exp Eye Res 82:479-487

    Article  CAS  PubMed  Google Scholar 

  • Rodriguez-Galindo C, Radomski KM, Stewart CF, Furman W, Santana VM, Houghton PJ (2000) Clinical use of topoisomerase I inhibitors in anticancer treatment. Med Pediatr Oncol 35:385-402

    Article  CAS  PubMed  Google Scholar 

  • Rodriguez-Galindo C, Wilson MW, Haik BG et al (2003a) Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 21:2019-2025

    Article  CAS  PubMed  Google Scholar 

  • Rodriguez-Galindo C, Wilson MW, Haik BG et al (2003b) Treatment of metastatic retinoblastoma. Ophthalmology 110:1237-1240

    Article  PubMed  Google Scholar 

  • Rodriguez-Galindo C, Chantada GL, Haik B, Wilson MW (2007) Retinoblastoma: current treatment and future perspectives. Curr Treat Options Neurol 9:294-307

    Article  PubMed  Google Scholar 

  • Saarinen UM, Sariola H, Hovi L (1991) Recurrent disseminated retinoblastoma treated with high-dose chemotherapy, total body irradiation, and autologous bone marrow rescue. Am J Pediatr Hematol Oncol 13:315-319

    Article  CAS  PubMed  Google Scholar 

  • Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG (2007) Macular retinoblastoma: Evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology 114:162-169

    Article  PubMed  Google Scholar 

  • Schiavetti A, Hadjistilianou T, Clerico A, Bonci E, Ragni G, Castello MA (2005) Conservative therapy in intraocular retinoblastoma. response/recurrence rate. J Pediatr Hematol Oncol 27:3-6

    Article  PubMed  Google Scholar 

  • Schmack I, Hubbard B, Kang SJ, Aaberg TM, Grossniklaus HE (2006) Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol 142:310-315

    Article  CAS  PubMed  Google Scholar 

  • Schouten-van Meeteren A, Moll A, Imhof S, Veerman A (2002) Chemotherapy for retinoblastoma: an expan­ding area of clinical research. Med Pediatr Oncol 38:428-438

    Article  CAS  PubMed  Google Scholar 

  • Schueler AO, Anastassiou G, Jurklies C, Havers W, Wieland R, Bornfeld N (2006) De novo intraocular retinoblastoma development after chemotherapy in patients with hereditary retinoblastoma. Retina 26:425-431

    Article  PubMed  Google Scholar 

  • Schvartzman E, Chantada G, Fandiño A, de Dávila MT, Raslawski E, Manzitti J (1996) Results of a stage-based protocol for the treatment of retinoblastoma. J Clin Oncol 14:1532-1536

    CAS  PubMed  Google Scholar 

  • Scott I, Murray T, Feuer W et al (1999) External beam radiotherapy in retinoblatoma. Tumor control and comparison of 2 techniques. Arch Ophthalmol 117:766-770

    Article  CAS  PubMed  Google Scholar 

  • Seregard S, Kock B, TRampe E (1995) Intravitreal chemotherapy for recurrent retinoblastoma in an only eye. Br J Ophthalmol 79:194-195

    Article  CAS  PubMed  Google Scholar 

  • Shields CL, Shields JA (1999) Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus 36:8-18

    CAS  PubMed  Google Scholar 

  • Shields CL, Shields JA, Needle M et al (1997) Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 104:2101-2111

    CAS  PubMed  Google Scholar 

  • Shields CL, Meadows AT, Shields JA, Carvalho C, Smith A (2001) Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol 119:1269-1272

    Article  CAS  PubMed  Google Scholar 

  • Shields CL, Honavar SG, Meadows AT et al (2002a) Chemoreduction plus focal therapy for retinoblastoma: Factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 133:657-664

    Article  PubMed  Google Scholar 

  • Shields CL, Honavar SG, Shields JA, Demirci H, Meadows AT, Naduvilath TJ (2002b) Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 120:460-464

    Article  PubMed  Google Scholar 

  • Shields CL, Shelil A, Cater J, Meadows AT, Shields JA (2003) Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol 121:1571-1576

    Article  PubMed  Google Scholar 

  • Shields CL, Mashayekhi A, Cater J et al (2005) Macular retinoblastoma managed with chemoreduction: Analysis of tumor control with or without adjuvant thermotherapy in 68 tumors. Arch Ophthalmol 123:765-773

    Article  PubMed  Google Scholar 

  • Simpson AE, Gilbert JA, Rudnick DE, Geroski DH, Aaberg TM, Edelhauser HF (2002) Transscleral diffusion of carboplatin. an in vitro and in vivo study. Arch Ophthalmol 120:1069-1074

    Article  CAS  PubMed  Google Scholar 

  • Smith MA, Rubinstein L, Ungerleider RS (1994) Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol 23:86-98

    Article  CAS  PubMed  Google Scholar 

  • Toma N, Hungerford J, Plowman P, Kingston J, Doughty D (1995) External beam radiotherapy for retinoblastoma: II Lens sparing technique. Br J Ophthalmol 79:112-117

    Article  CAS  PubMed  Google Scholar 

  • Urtti A (2006) Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58:1131-1135

    Article  CAS  PubMed  Google Scholar 

  • Uusitalo M, Van Quill K, Scott I, Matthay KK, Murray T, O’Brien J (2001) Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol 119:41-48

    Article  CAS  PubMed  Google Scholar 

  • Van Quill KR, Dioguardi PK, Tong CT et al (2005) Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 112:1151-1158

    Article  PubMed  Google Scholar 

  • Wilson MW, Haik BG, Liu T, Merchant TE, Rodriguez-Galindo C (2005) Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma. Am J Ophthalmol 140:397-406

    CAS  PubMed  Google Scholar 

  • Wilson MW, Fraga CH, Fuller CE et al (2006) Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation. Invest Ophthalmol Vis Sci 47:1269-1273

    Article  PubMed  Google Scholar 

  • Wilson MW, Haik BG, Billups CA, Rodriguez-Galindo C (2007) Incidence of new tumor formation in patients with hereditary retinoblastoma treated with primary systemic chemotherapy: is there a preventive effect? Ophthalmology 114:2077-2082

    Article  PubMed  Google Scholar 

  • Zelter M, Damel A, Gonzalez G, Schwartz L (1991) A prospective study on the treatment of retinoblastoma in 72 patients. Cancer 68:1685-1690

    Article  CAS  PubMed  Google Scholar 

  • Zhang J, Schweers B, Dyer MA (2004) The first knockout mouse model of retinoblastoma. Cell Cycle 3:952-959

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute and Children’s Hospital Harvard Medical School, Boston, MA, USA

    C. Rodriguez-Galindo (Associate Professor of Pediatrics)

Authors
  1. C. Rodriguez-Galindo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Rodriguez-Galindo .

Editor information

Editors and Affiliations

  1. Dana-Farber Cancer Institute &, Harvard Medical School, Binney St. 44, Boston, 02115, U.S.A.

    Carlos Rodriguez-Galindo

  2. Hamilton Eye Inst., University of Tennessee, Madison Avenue 930, Memphis, 38103, U.S.A.

    Matthew W. Wilson

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Rodriguez-Galindo, C. (2010). Chemotherapy in the Management of Retinoblastoma. In: Rodriguez-Galindo, C., Wilson, M. (eds) Retinoblastoma. Pediatric Oncology. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-89072-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-89072-2_6

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-89071-5

  • Online ISBN: 978-0-387-89072-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation